Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Park Andrea Eun Jae

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/15/2020

3. Issuer Name and Ticker or Trading Symbol

AgeX Therapeutics, Inc. [AGE]

(Last) (First) (Middle)

C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVENUE, SUITE 101

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /

(Street)

ALAMEDA, CA 94501

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.0001 par value	351	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	⁽¹⁾	9/30/2029	Common Stock	20000	$1.77	D
Option to Purchase Common Stock	⁽²⁾	5/14/2030	Common Stock	300000	$0.738	D

Explanation of Responses:
(1)	One quarter shall vest on October 1, 2020 and the remaining shall vest monthly over 36 months, based upon continuous service.
(2)	One quarter shall vest on May 15, 2021 and the remaining shall vest monthly over 36 months, based upon continuous service.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Park Andrea Eun Jae C/O AGEX THERAPEUTICS, INC. 965 ATLANTIC AVENUE, SUITE 101 ALAMEDA, CA 94501			Chief Financial Officer